DOP2022000281A - Antagonistas del receptor de melanocortina 4 y usos de estos - Google Patents

Antagonistas del receptor de melanocortina 4 y usos de estos

Info

Publication number
DOP2022000281A
DOP2022000281A DO2022000281A DO2022000281A DOP2022000281A DO P2022000281 A DOP2022000281 A DO P2022000281A DO 2022000281 A DO2022000281 A DO 2022000281A DO 2022000281 A DO2022000281 A DO 2022000281A DO P2022000281 A DOP2022000281 A DO P2022000281A
Authority
DO
Dominican Republic
Prior art keywords
compounds
salts
melanocortin
receptor antagonists
anorexia
Prior art date
Application number
DO2022000281A
Other languages
English (en)
Inventor
Christopher Smith Aaron
Forrest Sammons Matthew
Renee Garnsey Michelle
Ryan Butler Christopher
Yang Qingyi
Alexander Ogilvie Kevin
Polivkova Jana
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2022000281A publication Critical patent/DOP2022000281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se describen compuestos de la Fórmula I: I y sus sales aceptables desde el punto de vista farmacéutico, en donde R1, R2, R3, X1, Y1, Y2, Y3, Y4 e Y5 se definen en la presente; su uso como antagonistas de MC4R; composiciones farmacéuticas que contienen tales compuestos y sales; el uso de tales compuestos y sales para tratar, por ejemplo, caquexia, anorexia o anorexia nerviosa; e intermediarios y procesos para preparar tales compuestos y sales.
DO2022000281A 2020-06-09 2022-12-08 Antagonistas del receptor de melanocortina 4 y usos de estos DOP2022000281A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036798P 2020-06-09 2020-06-09
US202163167271P 2021-03-29 2021-03-29
PCT/IB2021/054970 WO2021250541A1 (en) 2020-06-09 2021-06-07 Spiro compounds as melanocortin 4 receptor antagonists and uses thereof

Publications (1)

Publication Number Publication Date
DOP2022000281A true DOP2022000281A (es) 2023-01-15

Family

ID=76422026

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000281A DOP2022000281A (es) 2020-06-09 2022-12-08 Antagonistas del receptor de melanocortina 4 y usos de estos

Country Status (23)

Country Link
US (2) US11643412B2 (es)
EP (1) EP4161927B1 (es)
JP (1) JP7288554B1 (es)
KR (1) KR20230011968A (es)
CN (1) CN116113635A (es)
AU (1) AU2021289169B2 (es)
BR (1) BR112022024527A2 (es)
CA (1) CA3186348A1 (es)
CL (1) CL2022003503A1 (es)
CO (1) CO2022017790A2 (es)
CR (1) CR20220632A (es)
DK (1) DK4161927T3 (es)
DO (1) DOP2022000281A (es)
EC (1) ECSP22093794A (es)
FI (1) FI4161927T3 (es)
IL (1) IL298891A (es)
LT (1) LT4161927T (es)
MX (1) MX2022015706A (es)
PE (1) PE20231215A1 (es)
TW (1) TWI843949B (es)
UY (1) UY39260A (es)
WO (1) WO2021250541A1 (es)
ZA (1) ZA202213427B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024173905A1 (en) * 2023-02-17 2024-08-22 Endevica Bio, Inc. Methods of preventing and/or treating side effects associated with anti-cancer agents using non-naturally occurring melanocortin analogs with anti-gdf-15 antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
RU2001103044A (ru) 1998-07-06 2003-08-10 Бристол-Маерс Сквибб Ко. (Us) Бенилсульфонамиды в качестве двойных антагонистов ангиотензиновых эндотелиновых рецепторов
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
EP1753748B1 (en) 2004-05-12 2009-07-29 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
US8293900B2 (en) * 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007096763A2 (en) 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
WO2007114323A1 (ja) 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
FR2937868B1 (fr) 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2210885A1 (en) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
WO2010096854A1 (en) 2009-02-27 2010-09-02 Mimetica Pty Ltd Methods of modulating the activity of the mc3 and/or mc4 receptors and treatment of conditions related to these receptors
KR101295937B1 (ko) 2009-03-11 2013-08-14 화이자 인코포레이티드 글루코카이네이즈 억제제로서 사용되는 벤조푸라닐 유도체
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
JP2012520868A (ja) 2009-03-20 2012-09-10 ファイザー・インク ３−オキサ−７−アザビシクロ［３．３．１］ノナン
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
BRPI1014636A2 (pt) 2009-06-05 2016-04-05 Pfizer moduladores de gpr 119
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
TW201643138A (zh) 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶（ｈｄａｃ）抑制劑之３－螺－７－異羥肟酸四氫萘
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
TR201618240A2 (tr) 2016-12-09 2017-01-23 Ahmet Elibol Aort kapak koruyucu kök replasman ameli̇yatlarinda kullanilan ölçüm ve si̇mülasyon terti̇bati
JP6637641B1 (ja) 2016-12-16 2020-01-29 ファイザー・インク Ｇｌｐ−１受容体アゴニストおよびその使用
BR112019014688A2 (pt) * 2017-01-20 2020-02-18 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl
NL2019545B1 (en) 2017-09-14 2019-03-27 Univ Delft Tech Instrument for minimal invasive surgical operations, comprising a rod or catheter and a tip mounted on the rod or catheter with an elastically deformable element

Also Published As

Publication number Publication date
CR20220632A (es) 2023-01-23
BR112022024527A2 (pt) 2022-12-27
CN116113635A (zh) 2023-05-12
CL2022003503A1 (es) 2023-09-01
KR20230011968A (ko) 2023-01-25
AU2021289169A1 (en) 2023-01-19
EP4161927B1 (en) 2024-08-07
FI4161927T3 (fi) 2024-10-03
CO2022017790A2 (es) 2022-12-20
WO2021250541A1 (en) 2021-12-16
DK4161927T3 (da) 2024-08-26
JP2023525394A (ja) 2023-06-15
ZA202213427B (en) 2023-07-26
TWI843949B (zh) 2024-06-01
UY39260A (es) 2022-01-31
IL298891A (en) 2023-02-01
JP7288554B1 (ja) 2023-06-07
CA3186348A1 (en) 2021-12-16
US20230174532A1 (en) 2023-06-08
US11643412B2 (en) 2023-05-09
PE20231215A1 (es) 2023-08-17
ECSP22093794A (es) 2023-01-31
US20230019853A1 (en) 2023-01-19
EP4161927A1 (en) 2023-04-12
MX2022015706A (es) 2023-01-24
TW202204357A (zh) 2022-02-01
AU2021289169B2 (en) 2024-01-04
LT4161927T (lt) 2024-09-25

Similar Documents

Publication Publication Date Title
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CO2022008675A2 (es) Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t
AR049706A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PE20141409A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
DOP2009000148A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
DOP2022000281A (es) Antagonistas del receptor de melanocortina 4 y usos de estos
AR071857A1 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
CL2020001817A1 (es) Moduladores del receptor c5a
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
SV2010003779A (es) Inhibidores de ciclopropil-polimerasa ref. tipo193 pct/slv/fd/1vh
PE20240775A1 (es) Compuestos antivirales
CL2020001564A1 (es) Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina.
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
PE20160284A1 (es) Derivados de amida como antogonistas del receptor de acido lisofosfatidico
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
PE20060881A1 (es) Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos
CL2022003041A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
ECSP22049160A (es) Derivados de bencimidazol
AR066712A1 (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa, una composicion farmaceutica que las comprende y su uso en eltratamiento de enfermedades mediadas por la inhibicion de la sintesis del peptido beta-amiloide.